BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8913266)

  • 1. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
    Smith CD; Zhang X
    J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL
    Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the antitumor compound cryptophycin-52 with tubulin.
    Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
    Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
    Bai R; Durso NA; Sackett DL; Hamel E
    Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
    Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
    Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
    Hamel E
    Pharmacol Ther; 1992; 55(1):31-51. PubMed ID: 1287674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
    Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
    J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of arenastatin A with porcine brain tubulin.
    Morita K; Koiso Y; Hashimoto Y; Kobayashi M; Wang W; Ohyabu N; Iwasaki S
    Biol Pharm Bull; 1997 Feb; 20(2):171-4. PubMed ID: 9057981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10.
    Edler MC; Fernandez AM; Lassota P; Ireland CM; Barrows LR
    Biochem Pharmacol; 2002 Feb; 63(4):707-15. PubMed ID: 11992639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of estramustine with tubulin isotypes.
    Laing N; Dahllöf B; Hartley-Asp B; Ranganathan S; Tew KD
    Biochemistry; 1997 Jan; 36(4):871-8. PubMed ID: 9020786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
    Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct and overlapping binding sites for IKP104 and vinblastine on tubulin.
    Chaudhuri AR; Tomita I; Mizuhashi F; Murata K; Ludueña RF
    J Protein Chem; 1998 Oct; 17(7):685-90. PubMed ID: 9853684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
    Owellen RJ; Hartke CA; Dickerson RM; Hains FO
    Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of maytansine to tubulin: competition with other mitotic inhibitors.
    Lin CM; Hamel E; Wolpert-DeFilippes MK
    Res Commun Chem Pathol Pharmacol; 1981 Mar; 31(3):443-51. PubMed ID: 7255878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.